* MediciNova Inc MNOV.OQ MNOV.O is expected to show no
change
in quarterly revenue when it reports results on February 14
(estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for MediciNova Inc is for a
loss
of 8 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for MediciNova
Inc is
$16.50, above its last closing price of $1.42.
This summary was machine generated February 12 at 23:19 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)